EMG
SPRY icon

ETF Managers Group’s ARS Pharmaceuticals SPRY Stock Holding History

ETF Managers Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$207K Buy
31,789
+7,998
+34% +$61.4K 0.01% 581
2022
Q4 		$203K Buy
23,791
+13,323
+127% +$86.4K 0.01% 476
2022
Q3 		$55K Sell
10,468
-636
-6% -$3.13K ﹤0.01% 668
2022
Q2 		$49K Buy
11,104
+464
+4% +$1.62K ﹤0.01% 710
2022
Q1 		$37K Buy
10,640
+35
+0.3% +$152 ﹤0.01% 669
2021
Q4 		$70K Sell
10,605
-1,204
-10% -$9.78K ﹤0.01% 652
2021
Q3 		$125K Buy
11,809
+1,514
+15% +$37.3K ﹤0.01% 632
2021
Q2 		$325K Sell
10,295
-431
-4% -$13.8K 0.01% 583
2021
Q1 		$435K Buy
+10,726
New +$508K 0.01% 511

Other funds holding SPRY

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ETF Managers Group's SPRY Position: Q1 2023 in Review

ETF Managers Group increased its ARS Pharmaceuticals (SPRY) stake by 34% in Q1 2023, buying an estimated $61.4K and bringing the position to 31,789 shares worth $207K. The position accounts for 0.01% of the portfolio, ranked #581.

ETF Managers Group first reported a position in SPRY in Q1 2021 and has held it in 9 quarters since. The position peaked at $435K in Q1 2021. 89 funds tracked by Wall St. Rank hold SPRY as of Q1 2023.

  • ETF Managers Group held 31,789 shares of ARS Pharmaceuticals worth $207K as of Q1 2023.
  • ETF Managers Group bought 7,998 ARS Pharmaceuticals shares in Q1 2023, an estimated $61.4K.
  • ARS Pharmaceuticals made up 0.01% of ETF Managers Group's portfolio in Q1 2023, its #581 holding.
  • ETF Managers Group first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 9 quarters since.
  • ETF Managers Group's ARS Pharmaceuticals position peaked at $435K in Q1 2021.
  • 89 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.